Benign Prostatic Hyperplasia Surgical Treatment Market Analysis APAC, Europe, North America, South America & MEA - US, Canada, Germany, UK, Japan, China, India - Size and Forecast 2025-2029

Benign Prostatic Hyperplasia Surgical Treatment Market Size 2025-2029

The benign prostatic hyperplasia surgical treatment market is projected to grow by USD 4.9 million, exhibiting a CAGR of 5.1% during the forecast period. Access precise market valuations upon report purchase.
The global benign prostatic hyperplasia surgical treatment market is propelled by the expanding aging population and the increasing prevalence of benign prostatic hyperplasia (BPH). This condition, characterized by the enlargement of the prostate gland, leads to significant demand for surgical interventions. The rising incidence of obesity in males, closely associated with BPH, further fuels market growth. While minimally invasive surgeries gain preference for their reduced recovery times and fewer complications, the high growth potential of emerging economies and favorable funding for BPH drug development also shape the market landscape.

To access the full market forecast and comprehensive analysis, Buy Now

How is this market segmented?

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in USD bn for the period 2025-2029, as well as historical data from 2019-2024 for the following segments:

• Drug Type
  • Alpha-blockers
  • 5-Alpha Reductase Inhibitors
  • Other Drug Types
• Type
  • Transurethral Resection of the Prostate (TURP)
  • Laser Surgeries
  • Urolift Procedures
  • Rezum Procedures
  • Other Procedures
• Therapy
  • Monotherapy
  • Combination Drug Therapy
• End User
  • Hospitals
  • Ambulatory Surgery Centers & Clinics
  • Home Care Settings
• APAC
  • China
  • India
  • Japan
  • Australia
  • Rest of APAC
  Europe
  • Germany
  • Spain
  • Italy
  • UK
  • Rest of Europe
  North America
  • US
  • Canada
  South America & MEA
  • Brazil
  • UAE
  • South Africa
  • Others

• Type
  • Laser Surgeries: Laser surgeries are gaining traction due to their minimally invasive nature and reduced recovery time.
  • Other Procedures: Other procedures include various alternative and emerging techniques, contributing to market innovation.
  • Rezum Procedures: Rezum procedures are gaining popularity due to their ability to provide targeted treatment with minimal side effects.
  • Urolift Procedures: Urolift procedures are expected to see growth as a less invasive option with minimal impact on sexual function.
  • Transurethral Resection of the Prostate (TURP): TURP remains a widely used surgical method and a significant market segment.
• Therapy
  • Monotherapy: Monotherapy remains a common treatment approach, particularly for initial management of BPH symptoms.
  • Combination Drug Therapy: Combination drug therapy is used for patients requiring more aggressive symptom management.
• End User
  • Hospitals: Hospitals are a major end-user segment, providing a wide range of surgical and medical treatments for BPH.
  • Home Care Settings: Home care settings are growing due to the increasing use of oral medications and remote monitoring.
  • Ambulatory Surgery Centers & Clinics: Ambulatory surgery centers and clinics offer cost-effective and convenient settings for BPH procedures.
• Drug Type
  • Alpha-blockers: This segment maintains a substantial market share due to its efficacy in managing BPH symptoms.
  • Other Drug Types: This segment includes combination therapies and emerging drugs, anticipated to show growth due to tailored treatment approaches.
  • 5-Alpha Reductase Inhibitors: The 5-alpha reductase inhibitors segment is expected to grow as a treatment option for reducing prostate size.

Regional Analysis

• APAC: The Asia-Pacific region is expected to exhibit the highest growth rate In the benign prostatic hyperplasia surgical treatment market. This is primarily attributed to the presence of a large target patient population in China and India, coupled with improving healthcare infrastructure and increasing awareness regarding BPH treatment options. Rapid economic development and rising healthcare expenditure In these countries are also significant factors driving market growth. Furthermore, the expanding geriatric population and favorable government initiatives aimed at enhancing treatment accessibility contribute to the region's growth momentum.
• Europe: Europe holds a substantial share in the benign prostatic hyperplasia surgical treatment market, with Germany and the UK being key contributors. The region's growth is driven by a well-established healthcare system, high awareness levels among the population, and the availability of advanced treatment technologies. The presence of major market players and favorable reimbursement policies further support market expansion. Additionally, a strong focus on research and development activities contributes to the introduction of innovative surgical techniques and devices.
• North America: North America dominates the benign prostatic hyperplasia surgical treatment market due to high healthcare expenditure, technological advancements, and the presence of a large number of market players. The United States and Canada are at the forefront of adopting advanced surgical techniques and devices. Increasing R&D investments by key players are also expected to enhance the efficiency and accessibility of BPH surgical treatments in the region. The well-established healthcare infrastructure and proactive approach toward adopting innovative treatments contribute significantly to the region's leading position.
• South America & MEA: The South America and Middle East & Africa regions represent emerging markets with considerable growth potential in the benign prostatic hyperplasia surgical treatment sector. Brazil is experiencing growth in its healthcare infrastructure and increasing awareness of BPH treatment. The UAE is emerging as a medical tourism hub, attracting investments in advanced healthcare facilities. As healthcare access improves and awareness increases, these regions are expected to offer lucrative opportunities for market players to expand their presence and introduce advanced BPH surgical solutions.

Market Dynamics

Our benign prostatic hyperplasia surgical treatment market researchers analyzed the data with 2024 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

What are the key market drivers leading to the rise in adoption of benign prostatic hyperplasia surgical treatment market?

Expanding aging population and increasing prevalence of benign prostatic hyperplasia.  The global rise In the aging population is directly correlated with a higher incidence of benign prostatic hyperplasia (BPH). As the geriatric demographic expands, the demand for effective BPH surgical treatments escalates. This demographic trend is particularly pronounced in developed nations, where longer life expectancies and improved healthcare access contribute to a larger pool of individuals seeking BPH management. The increasing awareness and diagnosis rates further amplify the need for advanced surgical interventions, driving market growth. This creates a sustained demand for innovative and efficient BPH surgical solutions. 

What are the market trends shaping the benign prostatic hyperplasia surgical treatment market?

Growing preference for minimally invasive surgeries. There is a growing preference for minimally invasive surgical techniques in the benign prostatic hyperplasia (BPH) surgical treatment market. These procedures, such as laser therapies, UroLift, and Rezum, offer numerous advantages over traditional open surgeries, including smaller incisions, reduced pain, shorter hospital stays, and faster recovery times. Patients are increasingly seeking these options to minimize disruption to their daily lives and reduce the risk of complications. This shift is further fueled by technological advancements and the increasing availability of minimally invasive devices, leading to greater adoption by urologists and enhanced patient outcomes. The trend towards minimally invasive approaches is transforming the BPH surgical treatment landscape. 

What challenges does the benign prostatic hyperplasia surgical treatment market face?

Side effects associated with benign prostatic hyperplasia medications. Medications commonly prescribed for benign prostatic hyperplasia (BPH) treatment often come with a range of side effects that can deter patient compliance and preference for surgical interventions. Alpha-blockers, while effective in relieving urinary symptoms, may cause orthostatic hypotension, dizziness, and retrograde ejaculation. Similarly, 5-alpha reductase inhibitors, used to reduce prostate size, can lead to sexual dysfunction, decreased libido, and gynecomastia. These side effects can significantly impact patients' quality of life, prompting them to explore surgical options that offer a more permanent solution with potentially fewer systemic adverse effects. Managing these side effects remains a key challenge In the BPH treatment landscape.

Key Companies & Market Insights

Leading companies are implementing strategies such as product innovations, acquisitions, and geographic expansions to enhance their market position. Key players in the benign prostatic hyperplasia surgical treatment market include:

• GlaxoSmithKline PLC
• Eli Lilly and Company
• Astellas Pharma Inc.
• Viatris Inc.
• Asahi Kasei Corporation
• Organon & Co.
• Alembic Pharmaceuticals Limited
• Teleflex Incorporated
• Boston Scientific Corporation
• Olympus Corporation
• PROCEPT BioRobotics Corporation
• Coloplast Group
• IPG Photonics Corporation
• ProstaLund Ab
• Karl Storz Se & Co. KG
• Richard Wolf GmbH
• Quanta System
• Asclepion Laser Technologies GmbH
• Cook Medical
• SRS Medical
• PNN Medical A/S
• Allium
• Urologix, LLC
• Medifocus, Inc.

These companies are strategically focused on product development, market expansion, and partnerships to maintain their competitive edge in the growing benign prostatic hyperplasia surgical treatment market.